Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
Avita Medical Initiates European Trial Using ReCell in the Management of Chronic Lower Limb Ulcers

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwire) -- 11/20/12 --


  • UP TO FIVE EUROPEAN CENTERS TO PARTICIPATE
  • PRELIMINARY STUDIES IN TREATMENT OF VENOUS LEG ULCERS YIELD POSITIVE RESULTS: DEMONSTRATE ACCELERATED HEALING AND REDUCED PAIN AS COMPARED WITH CURRENT STANDARD OF CARE
  • SUBSTANTIAL MARKET; US ANNUAL LOWER LIMB ULCER TREATMENT COSTS $25 BILLION

Regenerative medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) has initiated a multicenter randomized control study on the use of ReCell® Spray-On Skin® in the treatment of venous leg ulcers. Up to five European centers from countries including the United Kingdom, Germany, France and Denmark will participate in the study.

Lower limb ulcers (LLUs), which include venous leg ulcers and diabetic foot ulcers, are a major healthcare problem in developed countries due to their prevalence, high cost of treatment and significant impact on patient quality of life. LLUs afflict nearly 1.5% of the general population in OECD countries and up to 3% over the age of 70 years. The expense of treating LLUs imposes a major financial burden on healthcare systems. In the US alone some 6.5 million people suffer from LLUs with associated treatment costs estimated in excess of US$25 billion per annum with similar prevalence and expense documented in the UK, Germany and France. The costs to patients include associated morbidity, pain, lack of mobility and lost work days and wages.

In preliminary open-label studies ReCell was used at four European centers to treat approximately 80 patients suffering from venous leg ulcers and diabetic foot ulcers. Across study centers patients' average age was approximately 70 years, wounds were open an average of approximately 13 months and averaged approximately 21 cm2 in size.

Results of these preliminary studies have been encouraging. Over 70% of patients showed complete healing of the wound within 7-12 weeks following a single treatment with ReCell. With the current standard of care treatment it would be expected that approximately 43% of these wounds would have achieved closure during this period, thus ReCell appears to yield a highly significant positive effect on wound healing. Pain, a critical indicator of quality of life, was reported as being significantly reduced or eliminated within 72 hours following the ReCell treatment.

These data have been presented at congresses and have been submitted as separate papers for publication in peer-reviewed journals.

Given the positive results achieved in preliminary studies, Avita has initiated a randomized control study with leading clinicians at up to 5 European centers. Up to 80 patients will be enrolled in the study. Study protocols have been submitted for approval by the relevant ethics review boards at each center. It is anticipated that enrolment in the study will commence during the 1st quarter of 2013.

Dr. William Dolphin, CEO of Avita Medical, said, "The early results achieved in the treatment of chronic ulcers with ReCell are highly promising. These are hard-to-heal ulcers that pose an enormous burden on healthcare systems and seriously impact on patient's quality of life.

"ReCell is approved for use in Europe, Australia and other markets with over 4500 procedures conducted to date, mainly for burns. Improved leg ulcer treatment will provide tremendous relief for ulcer patients, potentially deliver significant cost savings to financially stressed healthcare systems and may open additional very large markets for ReCell."

ABOUT AVITA MEDICAL LTD.
Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. An FDA trial on the safety and efficacy of ReCell is in process.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2159670

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Avita Medical Ltd.
Stella Sung, Ph.D.
Business Development Officer
Phone:+1 818-356-9400
Email: ssung@avitamedical.com

Investor Relations:
ProActive Capital Resources Group, LLC
Jeff Ramson
CEO
641 Lexington Avenue, 6th Floor
New York, NY. 10022
Phone:+1 646-863-6893
Email: jramson@proactivecapitalgroup.com

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

SOA World Latest Stories
Express Logic, Inc., the worldwide leader in royalty-free real-time operating systems (RTOSes), introduces X-Ware™, an integrated, optimized, comprehensive middleware solution that provides a solid foundation for Internet of Things (IoT) development. X-Ware consists of Express Logic’s ...
Many mid-market companies have invested significant time and resources to secure and back up their servers, client computers, data, and overall network infrastructure in what was the traditional client-server setup. Now, what were considered emerging technologies just a few years ago, ...
I've been writing recently about the dimensions of Big Data in the IoT: urgency, importance, frequency, consequences, remedy, cost. You can find my stories on IoT Journal or at my personal website. The big item missing from this list is, of course, size. How big are individual messa...
Processes are not documented and reused by a set of individuals because they lead to failure. Like design patterns, they are documented and reused because they lead to success. They are all put together by very talented people who have successfully used them to develop software multip...
Vormetric on Tuesday announced that Rackspace Hosting has joined the Cloud Partner program, and will be offering encryption and key management services to customers via Vormetric's Transparent Encryption solution. Vormetric's Transparent Encryption combines the performance, flexibility...
I'm reading a McKinsey report from May 2013 that talks about 12 disruptive technologies, including cloud computing and the Internet of Things (IoT). I'll focus on the IoT here. The report estimates the IoT Internet to be worth between $2.7 and $6.2 trillion by the year 2025.(The world'...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE